In vitro efficacy of imipenem in combination with six antimicrobial agents against Mycobacterium abscessus

International Journal of Antimicrobial Agents

Volumn 30, Issue 3, 2007, Pages 255-258

  Miyasaka, Tomomitsu ^a,b,c   Kunishima, Hiroyuki ^d   Komatsu, Mayumi ^b   Tamai, Kiyoko ^a   Mitsutake, Kotaro ^d   Kanemitsu, Keiji ^d   Ohisa, Yoshiharu ^c   Yanagisawa, Hideji ^a   Kaku, Mitsuo ^c,d  

^a Miroku Medical Laboratory Inc   (Japan)

^b Miyagi Medical Association   (Japan)

^c TOHOKU UNIVERSITY HOSPITAL   (Japan)

^d Laboratory Diagnostics   (Japan)

Author keywords

Drug combination; Imipenem; MIC; Mycobacterium abscessus

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CEFOXITIN; CLARITHROMYCIN; IMIPENEM; LEVOFLOXACIN; MINOCYCLINE; MOXIFLOXACIN; TOBRAMYCIN;

ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL STRAIN; DRUG EFFICACY; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DRUG SYNERGISM; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; QUALITY CONTROL; SPUTUM; WOUND INFECTION;

EID: 34547226095     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.05.003     Document Type: Article

References (14)

1. Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 16 (2003) 319-354
2. Olivier K.N., Weber D.J., Wallace Jr. R.J., et al. Nontuberculous mycobacteria. I. Multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 167 (2003) 828-834
3. De Groote M.A., and Huitt G. Infections due to rapidly growing mycobacteria. Clin Infect Dis 42 (2006) 1756-1763
4. Brown-Elliott B.A., and Wallace Jr. R.J. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmented rapidly growing mycobacteria. Clin Microbiol Rev 15 (2002) 716-746
5. Sanguinetti M., Ardito F., Fiscarelli E., et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol 39 (2001) 816-819
6. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 1997;156:S1-S25.
7. Wallace Jr. R.J., Tanner D., Brennan P.J., and Brown B.A. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 119 (1993) 482-486
8. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, Nocardiae, and other aerobic actinomycetes. Approved standard. M24-A. Wayne, PA: NCCLS; 2003.
9. Matoba A.Y., Lee B.L., Robinson N.M., Penland R., and Osato M.S. Combination drug testing of Mycobacterium chelonae. Invest Ophthalmol Vis Sci 34 (1993) 2786-2789
10. Hindler J. Antimicrobial susceptibility testing. In: Henry D.I. (Ed). Clinical microbiology procedures handbook (1992), American Society for Microbiology, Washington, DC
11. Kusunoki S., Ezaki T., Tamesada M., et al. Application of colorimetric microdilution plate hybridization for rapid genetic identification of 22 Mycobacterium species. J Clin Microbiol 29 (1991) 1596-1603
12. Eliopoulos G.M., and Moellering Jr. R.C. Antimicrobial combinations. In: Lorian V. (Ed). Antibiotics in laboratory medicine. 4th ed. (1996), Williams and Wilkins Co., Baltimore, MD
13. Koh W.J., Kwon O.J., Jeon K., et al. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 129 (2006) 341-348
14. Woods G.L., Bergmann J.S., Witebsky F.G., et al. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J Clin Microbiol 37 (1999) 1676-1682